Overview
- Curaleaf disclosed on Aug. 18 a takeover proposal for Aurora that offers 0.3463 Curaleaf shares plus $0.75 cash per Aurora share and values Aurora at roughly $260 million with a price cap that can rise to $5 per share.
- Aurora has traded near the offer price while reporting recent weakness, including a $0.07 per-share loss in fiscal Q1 2027 and about $93.7 million in reported debt, which made the company a takeover target.
- Curaleaf says it seeks Aurora largely for its European market share so Curaleaf can expand its global footprint and apply its operational scale to Aurora’s products and retail network.
- The U.S. Drug Enforcement Administration has finished hearings on rescheduling but not issued a decision, and industry participants note that a move from Schedule I to Schedule III would lift Section 280E tax limits and boost after-tax cash flow for buyers.
- Peer operators such as Green Thumb are preparing to act selectively by filing DEA registrations and expanding buybacks, and the sector is likely to see disciplined M&A once regulatory clarity arrives.